Abbvie Inc.
$607.8M 1,721,235 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC reported $525,199,355.13 across General Payments, Research, and Ownership to 216,602 physicians and teaching hospitals across 223,349 transactions.
- $525.2M Top 1% payer
- All-tracks total
- 223,349 Top 1% volume
- Transactions
- 216,602 Top 1% reach
- Recipients
- −$124.2K
- General Payments vs PY2023
Merck Sharp & Dohme LLC reported $525,199,355.13 across all CMS Open Payments tracks (General + Research + Ownership) to 216,602 physicians and teaching hospitals in Program Year 2024 - ranking #6 of 1,925 reporting manufacturers (3.8% of the all-tracks industry total); General Payments alone were $23,231,676.39, averaging $2.4K per recipient.
How Merck Sharp & Dohme LLC's $525.2M all-tracks total breaks down
Merck Sharp & Dohme LLC's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
A
98/100
Total payments
A
100/100
Transaction volume
A
100/100
Physician reach
A
100/100
Payment type diversity
A
90/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer merck-sharp-dohme-llc Merck Sharp & Dohme LLC
$525.2M · #6/1,925 · 3.8% industry · PY2024
- TOT $525.2M
- RANK #6
- SHARE 3.8%
- TXN 223,349
- RCP 216,602
- CAT 7
- GEN $23.2M
- ΔGEN −$124.2K
- TOP1 5.6%
- PY 2024
Volume peers
Nearest volume peer: Abbvie Inc. ($607.8M)
Merck Sharp & Dohme LLC sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Merck Sharp & Dohme LLC's CMS-reported General Payments decreased by $124.2K (−0.5%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: MERCK SHARP & DOHME LLCPY2023: MERCK SHARP & DOHME LLCPY2024: Merck Sharp & Dohme LLC. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $23,355,830.00
- PY2024
- $23,231,676.39
What the Data Shows for Merck Sharp & Dohme LLC
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For Merck Sharp & Dohme LLC, that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
"Consulting Fee" leads the 7-category general-payment breakdown below at $8.2M (35.5% of General Payments, 2,611 transactions) - see our methodology for how research and ownership payments are reported separately.
General Payment Breakdown by Type
"Consulting Fee" leads Merck Sharp & Dohme LLC's 7-category general-payment breakdown at $8.2M, 35.5% of the reported total.
Merck Sharp & Dohme LLC reports 7 general-payment categories - the top three are Consulting Fee (35.5%), Food and Beverage (19.8%), and Compensation for Services Other Than Consulting (18.5%). The remaining 4 categories make up 26.2% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Merck Sharp & Dohme LLC divides its payments
Top payment categories by total reported dollar volume
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $8.2M | 2,611 | 35.5% |
| Food and Beverage | $4.6M | 204,906 | 19.8% |
| Compensation for Services Other Than Consulting | $4.3M | 1,188 | 18.5% |
| Travel and Lodging | $3.0M | 5,673 | 12.7% |
| Grant | $2.5M | 53 | 10.8% |
| Space Rental or Facility Fees | $590.8K | 226 | 2.5% |
| Education | $32.5K | 1,945 | 0.1% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $3,677,249.39 (15.8%) of $23,231,676.39 in this company's General Payments records across 96,424 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Merck Sharp & Dohme LLC
The five named recipients with the highest reported General Payments from this company
- 1
Marc Sabatine
$1,298,565.69 across 16 reported transactions
- 2
Craig B Thompson
$771,479.70 across 1 reported transactions
- 3
Hospital Of The Univ Of Penna
$755,600.00 across 11 reported transactions
- 4
Rush University Medical Center
$573,354.00 across 10 reported transactions
- 5
Montefiore Medical Center
$278,250.00 across 3 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Merck Sharp & Dohme LLC ranks #6 of 1,925 by total payments (top 1% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,735 of 1,838 by HHI (bottom 6% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Bayer Puerto Rico Inc. : $18.3K total payments, HHI 73
- Fisher & Paykel Healthcare Inc : $225.2K total payments, HHI 73
- ViiV Healthcare Company : $8.9M total payments, HHI 73
- Sanofi-Aventis U.s. LLC : $9.2M total payments, HHI 72
- Dermavant Sciences, Inc. : $6.7M total payments, HHI 71
- Protega Pharmaceutials Inc : $48.5K total payments, HHI 71
- Merck Sharp & Dohme LLC (this company) : $23.2M total payments, HHI 69
- Life Molecular Imaging Ltd : $8.0K total payments, HHI 68
- Ironwood Pharmaceuticals, Inc : $659.4K total payments, HHI 68
- Novus Surgical Consultants : $122.1K total payments, HHI 68
- UCB, Inc. : $18.4M total payments, HHI 68
- Linus Health, Inc. : $4.8K total payments, HHI 67
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Merck Sharp & Dohme LLC's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Merck Sharp & Dohme LLC.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Merck Sharp & Dohme LLC.
Showing 6 of 1,924 companies with CMS-reported payment data.
AstraZeneca Pharmaceuticals LP
$428.2M 858,609 recipients
Compare payment profiles
Genentech, Inc.
$400.6M 2,544 recipients
Compare payment profiles
Eli Lilly and Company
$652.4M 8,748 recipients
Compare payment profiles
Midmark Corporation
$386.1M 378 recipients
Compare payment profiles
ModernaTX, Inc.
$665.3M 3,173 recipients
Compare payment profiles
Put this to use
Merck Sharp & Dohme LLC ranks #6 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See where Merck Sharp & Dohme LLC sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just Merck Sharp & Dohme LLC. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.